18 February 2016 - An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.

For more details, go to: http://uk.reuters.com/article/us-britain-alexion-idUKKCN0VR003